Combining immunotherapy with targeted radiation resulted in a greater response rate than immunotherapy alone in a phase 2 clinical trial in patients with early-stage, non-small-cell lung cancer led by Weill Cornell Medicine and NewYork-Presbyterian investigators. In view of the safety and efficacy of the treatment, a larger trial is warranted.
Immunotherapies, drugs that increase the immune system’s ability to detect and kill cancer cells, are becoming a mainstay of cancer treatments....